Immunoadsorption in Dermatology

Therapeutic Apheresis and Dialysis

Volumn 16, Issue 4, 2012, Pages 311-320

  Meyersburg, Damian ^a   Schmidt, Enno ^a   Kasperkiewicz, Michael ^a   Zillikens, Detlef ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Atopic dermatitis; Autoantibody; Immunoadsorption; Pemphigoid; Pemphigus; Treatment

Indexed keywords

AZATHIOPRINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; DEXAMETHASONE; DOXYCYCLINE; GLOBAFFIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSORBA; IMMUNOSUPPRESSIVE AGENT; IMTR 350; IMTR 360; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PREDNISOLONE; RITUXIMAB; SELESORB; THERASORB; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BLISTER; BRADYCARDIA; BULLOUS PEMPHIGOID; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DIVERTICULITIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; EPIDERMOLYSIS BULLOSA; EPIDERMOLYSIS BULLOSA ACQUISITA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPOTENSION; IMMUNOADSORPTION; LOW DRUG DOSE; LUNG EMBOLISM; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; PARANEOLASTIC PEMPHIGUS; PARANEOPLASTIC PEMPHIGUS; PARANEOPLASTIC VULGARIS; PEMPHIGOID GESTATIONIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REFRACTORY PEMPHIGUS; REMISSION; REVIEW; SKIN DISEASE; STAPHYLOCOCCUS INFECTION;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; DERMATITIS, ATOPIC; DERMATOLOGY; HUMANS; IMMUNOSORBENTS; PEMPHIGUS; SKIN; SKIN DISEASES, VESICULOBULLOUS;

EID: 84864130504     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01075.x     Document Type: Review

References (81)

1. Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010;302:241-53.
2. Hershko AY, Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci 2005;1051:635-46.
3. Rönspeck W, Brinckmann R, Egner R etal. Peptide based adsorbers for therapeutic immunoadsorption. Ther Apher Dial 2003;7:91-7.
4. Hiepe F, Pfuller B, Wolbart K etal. C1q: a multifunctional ligand for a new immunoadsorption treatment. Ther Apher 1999;3:246-51.
5. Kumlien G, Ullstrom L, Losvall A etal. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion 2006;46:1568-75.
6. Wallukat G, Muller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002;347:1806.
7. Sakai Y, Sakai S, Otsuka T etal. Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab. Ther Apher Dial 2009;13:179-85.
8. Soerensen H, Schneidewind-Mueller JM, Lange D etal. Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol Int 2006;26:409-15.
9. Bresci G, Romano A, Mazzoni A etal. Feasibility and safety of granulocytapheresis in Crohn's disease: a prospective cohort study. Gastroenterol Clin Biol 2010;34:682-6.
10. Liumbruno GM, Centoni PE, Molfettini P etal. Lymphocytapheresis in the treatment of psoriasis vulgaris. J Clin Apher 2006;21:158-64.
11. Watanabe Y, Yamada H. Leukocyte adsorption apheresis for the treatment of pyoderma gangrenosum. J Dermatol 2008;35:792-4.
12. Schmidt E, Zillikens D. The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 2011;108:399-405.
13. Anhalt GJ, Kim SC, Stanley JR etal. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323:1729-35.
14. Zimmermann J, Bahmer F, Rose C etal. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010;8:598-606.
15. Schoen H, Foedinger D, Derfler K etal. Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol 1998;134:706-10.
16. Sitaru C, Mihai S, Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res 2007;299:1-8.
17. Sharma P, Mao X, Payne AS. Beyond steric hindrance: the role of adhesion signaling pathways in the pathogenesis of pemphigus. J Dermatol Sci 2007;48:1-14.
18. Waschke J. The desmosome and pemphigus. Histochem Cell Biol 2008;130:21-54.
19. Zillikens D, Schmidt E, Reimer S etal. Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice. J Pathol 2001;193:117-24.
20. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982;306:1189-96.
21. Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009;7:434-40.
22. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008;337:a180.
23. Marazza G, Pham HC, Scharer L etal. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009;161:861-8.
24. Hirose M, Recke A, Beckmann T etal. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol 2011;187:1176-83.
25. Iwata H, Kamio N, Aoyama Y etal. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 2009;129:919-26.
26. Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996;98:1509-18.
27. Liu Z, Diaz LA, Troy JL etal. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993;92:2480-8.
28. Nishie W, Sawamura D, Goto M etal. Humanization of autoantigen. Nat Med 2007;13:378-83.
29. Schmidt E, Reimer S, Kruse N etal. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 2000;115:842-8.
30. Sitaru C, Mihai S, Otto C etal. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005;115:870-8.
31. Sitaru C, Schmidt E, Petermann S, Munteanu LS, Brocker EB, Zillikens D. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002;118:664-71.
32. Sárdy M, Kárpáti S, Merkl B etal. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002;195:747-57.
33. Kárpáti S. Dermatitis herpetiformis. Clin Dermatol 2012;30:56-9.
34. Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011;64:903-8.
35. Chams-Davatchi C, Esmaili N, Daneshpazhooh M etal. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007;57:622-8.
36. Bystryn JC, Rudolph JL. Pemphigus. Lancet 2005;366:61-73.
37. Kirtschig G, Middleton P, Bennett C etal. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010;(10):CD002292.
38. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009;(1):CD006263.
39. Kirtschig G, Murrell D, Wojnarowska F etal. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002;138:380-4.
40. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011;165:646-51.
41. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009;279:683-91.
42. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007;156:352-6.
43. Joly P, Mouquet H, Roujeau JC etal. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-52.
44. Schmidt E, Bröcker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008;34:56-64.
45. Amagai M, Ikeda S, Shimizu H etal. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009;60:595-603.
46. Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2011;65:1064-5.
47. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012;166:405-12.
48. Schmidt E, Goebeler M. CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev Dermatol 2008;3:259-78.
49. Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 2009;129:289-301.
50. Hertl M, Zillikens D, Borradori L etal. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008;6:366-73.
51. Enk A, Fierlbeck G, French L etal. Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges 2009;7:806-12.
52. Eming R, Rech J, Barth S etal. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006;212:177-87.
53. Luftl M, Stauber A, Mainka A etal. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003;149:598-605.
54. Matic G, Hofmann D, Winkler R etal. Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000;24:103-7.
55. Ogata K, Yasuda K, Matsushita M etal. Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method. J Dermatol 1999;26:236-9.
56. Schmidt E, Klinker E, Opitz A etal. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003;148:1222-9.
57. Frost N, Messer G, Fierlbeck G etal. Treatment of pemphigus vulgaris with protein A immunoadsorption: case report of long-term history showing favorable outcome. Ann N Y Acad Sci 2005;1051:591-6.
58. Shimanovich I, Herzog S, Schmidt E etal. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006;31:768-74.
59. Westermann L, Hügel R, Meier M etal. Glucosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J Dermatol 2011;38:1-4.
60. Shimanovich I, Nitschke M, Rose C etal. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008;158:382-8.
61. Günther C, Laske J, Frind A, Julius U, Pfeiffer C. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber. J Dtsch Dermatol Ges 2008;6:661-3.
62. Schmidt E, Zillikens D. Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 2009;7:296-300.
63. Pfutze M, Eming R, Kneisel A etal. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 2009;218:237-45.
64. Marker M, Derfler K, Monshi B etal. Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. J Dtsch Dermatol Ges 2011;9:27-31.
65. Behzad M, Möbs C, Kneisel A etal. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remissions in difficult to treat pemphigus. Br J Dermatol 2012;166:844-52.
66. Kasperkiewicz M, Shimanovich I, Meier M etal. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012;166:154-60.
67. Ino N, Kamata N, Matsuura C etal. Immunoadsorption for the treatment of bullous pemphigoid. Ther Apher 1997;1:372-6.
68. Herrero-González JE, Sitaru C, Klinker E etal. Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption. Clin Exp Dermatol 2005;30:519-22.
69. Recke A, Shimanovich I, Steve P etal. Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab. Hautarzt 2011;62:852-8.
70. Wohrl S, Geusau A, Karlhofer F, Derfler K, Stingl G, Zillikens D. Pemphigoid gestationis: treatment with immunoapheresis. J Dtsch Dermatol Ges 2003;1:126-30.
71. Kasperkiewicz M, Hoppe U, Zillikens D. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. Clin Exp Dermatol 2010;35:614-17.
72. Liu Z, Diaz LA, Swartz SJ etal. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol 1995;155:5449-54.
73. Niedermeier A, Eming R, Pfutze M etal. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 2007;143:192-8.
74. Kubisch I, Diessenbacher P, Schmidt E etal. Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol 2010;11:289-93.
75. Kwon EJ, Yamagami J, Nishikawa T etal. Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol 2008;22:1070-5.
76. Schmidt E, Zillikens D. Diagnosis and treatment of patients with autoimmune bullous disorders in Germany. Dermatol Clin 2011;29:663-71.
77. Zillikens D, Derfler K, Eming R etal. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007;5:881-7.
78. Pugliarello S, Cozzi A, Gisondi P etal. Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges 2011;9:12-20.
79. Belloni B, Ziai M, Lim A etal. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223-5.
80. Heil PM, Maurer D, Klein B etal. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:990-8.
81. Kasperkiewicz M, Schmidt E, Frambach Y etal. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 2011;127:267-70.